Published in Nat Immunol on November 16, 2008
The regulation of IL-10 production by immune cells. Nat Rev Immunol (2010) 9.18
Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat Immunol (2009) 2.23
Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nat Rev Drug Discov (2009) 2.00
The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs (2010) 1.79
Chromatin unfolding by Cdt1 regulates MCM loading via opposing functions of HBO1 and HDAC11-geminin. Cell Cycle (2010) 1.62
Histone deacetylase inhibition alters dendritic cells to assume a tolerogenic phenotype and ameliorates arthritis in SKG mice. Arthritis Res Ther (2011) 1.44
Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochim Biophys Acta (2010) 1.35
SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease. PLoS One (2011) 1.34
Cell type-specific regulation of IL-10 expression in inflammation and disease. Immunol Res (2010) 1.32
Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. Blood (2012) 1.27
Regulating the regulators: the post-translational code of class I HDAC1 and HDAC2. J Biomed Biotechnol (2010) 1.26
Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules (2015) 1.25
The redox basis of epigenetic modifications: from mechanisms to functional consequences. Antioxid Redox Signal (2011) 1.24
HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma. Blood (2011) 1.10
Histone deacetylase 1 and 2 are essential for normal T-cell development and genomic stability in mice. Blood (2013) 1.06
Myeloid-derived suppressor cells: the dark knight or the joker in viral infections? Immunol Rev (2013) 1.05
Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer. Immunol Cell Biol (2011) 1.05
Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. Br J Haematol (2009) 1.05
Targeting histone deacetyalses in the treatment of B- and T-cell malignancies. Invest New Drugs (2010) 1.05
Acetylation/deacetylation modulates the stability of DNA replication licensing factor Cdt1. J Biol Chem (2009) 1.05
Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors. J Biomed Biotechnol (2010) 1.02
HDAC inhibition and graft versus host disease. Mol Med (2011) 1.02
HDAC inhibitors and immunotherapy; a double edged sword? Oncotarget (2014) 0.97
Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. J Med Chem (2012) 0.97
Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy. Genes Cancer (2015) 0.95
Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10. J Immunol (2011) 0.95
Chronic alcohol exposure alters gene expression in HepG2 cells. Alcohol Clin Exp Res (2011) 0.95
The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients. Am J Hematol (2012) 0.94
Epigenetic control of cytokine gene expression: regulation of the TNF/LT locus and T helper cell differentiation. Adv Immunol (2013) 0.94
Epigenetic modulation of the immune function: a potential target for tolerance. Epigenetics (2013) 0.90
Regulation of immune responses by histone deacetylase inhibitors. ISRN Hematol (2012) 0.90
Acetylation and nuclear receptor action. J Steroid Biochem Mol Biol (2010) 0.89
Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma. Epigenetics (2014) 0.89
Histone deacetylase 7 promotes Toll-like receptor 4-dependent proinflammatory gene expression in macrophages. J Biol Chem (2013) 0.89
Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents. J Med Chem (2010) 0.89
The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells. Br J Pharmacol (2011) 0.89
Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells. Mol Immunol (2014) 0.88
Bacterial infection remodels the DNA methylation landscape of human dendritic cells. Genome Res (2015) 0.88
Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b. Haematologica (2009) 0.87
Histone deacetylase classes I and II regulate Kaposi's sarcoma-associated herpesvirus reactivation. J Virol (2013) 0.87
Dynamic DNA methylation patterns across the mouse and human IL10 genes during CD4+ T cell activation; influence of IL-27. Mol Immunol (2010) 0.87
Heat shock protein 90 stabilizes nucleolin to increase mRNA stability in mitosis. J Biol Chem (2011) 0.86
Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches. Cancer Control (2012) 0.86
A novel role for histone deacetylase 6 in the regulation of the tolerogenic STAT3/IL-10 pathway in APCs. J Immunol (2014) 0.86
From immunity to tolerance through HDAC. Nat Immunol (2009) 0.84
Eicosanoids in the innate immune response: TLR and non-TLR routes. Mediators Inflamm (2010) 0.84
Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention. Clin Cancer Res (2015) 0.83
Interleukin-10: a pleiotropic regulator in pregnancy. Am J Reprod Immunol (2014) 0.82
Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function. Mol Immunol (2014) 0.81
Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers. Leuk Res (2010) 0.81
The promise and perils of HDAC inhibitors in neurodegeneration. Ann Clin Transl Neurol (2014) 0.81
Histone deacetylase inhibition and dietary short-chain Fatty acids. ISRN Allergy (2011) 0.80
Mutagenesis studies of the 14 Å internal cavity of histone deacetylase 1: insights toward the acetate-escape hypothesis and selective inhibitor design. J Med Chem (2014) 0.80
Epigenetics of Peripheral B-Cell Differentiation and the Antibody Response. Front Immunol (2015) 0.80
Micro RNA-17-92 cluster mediates interleukin-4-suppressed IL-10 expression in B cells. Am J Transl Res (2016) 0.79
Gene expression mapping of histone deacetylases and co-factors, and correlation with survival time and 1H-HRMAS metabolomic profile in human gliomas. Sci Rep (2015) 0.79
Nuclear translocation of MEK1 triggers a complex T cell response through the corepressor silencing mediator of retinoid and thyroid hormone receptor. J Immunol (2012) 0.78
Differentially expressed epigenome modifiers, including aurora kinases A and B, in immune cells in rheumatoid arthritis in humans and mouse models. Arthritis Rheum (2013) 0.78
HDAC6 regulates LPS-tolerance in astrocytes. PLoS One (2011) 0.78
Epigenetic Control of Macrophage Polarisation and Soluble Mediator Gene Expression during Inflammation. Mediators Inflamm (2016) 0.78
Epigenetics in myeloid derived suppressor cells: a sheathed sword towards cancer. Oncotarget (2016) 0.78
Discovery of a Novel HDAC2 Inhibitor by a Scaffold-Merging Hybrid Query. Comb Chem High Throughput Screen (2015) 0.77
Histone Deacetylase 3 Is Required for Efficient T Cell Development. Mol Cell Biol (2015) 0.77
Targeting histone deacetylases: perspectives for epigenetic-based therapy in cardio-cerebrovascular disease. J Geriatr Cardiol (2015) 0.77
Epigenetic modifications and diabetic nephropathy. Kidney Res Clin Pract (2012) 0.76
Novel mechanisms underlying the immediate and transient global tolerization of splenic dendritic cells after vaccination with a self-antigen. J Immunol (2013) 0.76
Epigenetic Alterations in Fanconi Anaemia: Role in Pathophysiology and Therapeutic Potential. PLoS One (2015) 0.76
Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy. Oncolytic Virother (2015) 0.76
Micro RNA-19a suppresses interleukin-10 in peripheral B cells of patients with diabetic retinopathy. Am J Transl Res (2017) 0.75
An alternative approach to medical genetics based on modern evolutionary biology. Part 5: epigenetics and genomics. J R Soc Med (2009) 0.75
Proliferative status regulates HDAC11 mRNA abundance in nontransformed fibroblasts. Cell Cycle (2013) 0.75
Histone deacetylases in monocyte/macrophage development, activation and metabolism: refining HDAC targets for inflammatory and infectious diseases. Clin Transl Immunology (2016) 0.75
Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy. Cancers (Basel) (2015) 0.75
The Atypical Inhibitor of NF-κB, IκBζ, Controls Macrophage Interleukin-10 Expression. J Biol Chem (2016) 0.75
Tipifarnib-mediated suppression of T-bet-dependent signaling pathways. Cancer Immunol Immunother (2011) 0.75
Genome-Wide STAT3 Binding Analysis after Histone Deacetylase Inhibition Reveals Novel Target Genes in Dendritic Cells. J Innate Immun (2016) 0.75
HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases. Biomed Res Int (2016) 0.75
Interleukin-13 suppresses interleukin-10 via inhibiting A20 in peripheral B cells of patients with food allergy. Oncotarget (2016) 0.75
Transcriptomic changes throughout post-hatch development in Gallus gallus pituitary. J Mol Endocrinol (2016) 0.75
Disruption to schizophrenia-associated gene Fez1 in the hippocampus of HDAC11 knockout mice. Sci Rep (2017) 0.75
[Epigentics in rheumatic diseases]. Z Rheumatol (2011) 0.75
Micro RNA-155 plays a critical role in the initiation of food allergen-related inflammation in the intestine. Oncotarget (2017) 0.75
Class II and IV HDACs function as inhibitors of osteoclast differentiation. PLoS One (2017) 0.75
T-cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model. Blood (2017) 0.75
A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res (2001) 124.61
Dendritic cells and the control of immunity. Nature (1998) 56.54
Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol (2001) 25.63
Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol (2003) 15.65
Tolerogenic dendritic cells. Annu Rev Immunol (2001) 13.77
Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity (2008) 9.82
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature (2007) 7.34
Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity (1994) 7.22
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol (2008) 6.90
Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol (2005) 6.81
Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol (2001) 6.20
Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells. J Exp Med (1997) 5.72
A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes. J Exp Med (2000) 5.11
Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol (2001) 5.11
Thymic selection of CD8+ single positive cells with a class II major histocompatibility complex-restricted receptor. J Exp Med (1994) 4.91
Remote control of gene transcription. Hum Mol Genet (2005) 4.80
Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science (2002) 4.02
Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10. Immunity (2008) 3.26
The CD8alpha(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J Exp Med (2002) 2.93
Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem (2002) 2.82
Constitutive presentation of a natural tissue autoantigen exclusively by dendritic cells in the draining lymph node. J Exp Med (2002) 2.78
CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells. J Exp Med (1998) 2.69
A critical role for Stat3 signaling in immune tolerance. Immunity (2003) 2.41
Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia (2005) 2.15
Role of Stat3 in lipopolysaccharide-induced IL-10 gene expression. J Immunol (2000) 2.06
IL-10 gene expression is controlled by the transcription factors Sp1 and Sp3. J Immunol (2000) 2.04
ERK activation following macrophage FcgammaR ligation leads to chromatin modifications at the IL-10 locus. J Immunol (2005) 2.03
Negative regulation of histone deacetylase 8 activity by cyclic AMP-dependent protein kinase A. Mol Cell Biol (2004) 1.60
Interleukin (IL)-4 inhibits IL-10 to promote IL-12 production by dendritic cells. J Exp Med (2005) 1.59
Dynamic and transient remodeling of the macrophage IL-10 promoter during transcription. J Immunol (2006) 1.55
Differential regulation of interleukin-10 production by genetic and environmental factors--a twin study. Genes Immun (2002) 1.39
Chromatin-level regulation of the IL10 gene in T cells. J Biol Chem (2004) 1.36
Activation of the growth-differentiation factor 11 gene by the histone deacetylase (HDAC) inhibitor trichostatin A and repression by HDAC3. Mol Cell Biol (2004) 1.26
Chromatin remodeling and transcriptional activity of the bone-specific osteocalcin gene require CCAAT/enhancer-binding protein beta-dependent recruitment of SWI/SNF activity. J Biol Chem (2006) 1.24
Direct association between PU.1 and MeCP2 that recruits mSin3A-HDAC complex for PU.1-mediated transcriptional repression. Oncogene (2003) 1.09
Histone deacetylase 3 down-regulates cholesterol synthesis through repression of lanosterol synthase gene expression. J Biol Chem (2007) 0.98
Identification of a novel negative role of flagellin in regulating IL-10 production. Eur J Immunol (2007) 0.97
Histone deacetylases: purification of the enzymes, substrates, and assay conditions. Methods Enzymol (2004) 0.80
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med (2006) 8.26
Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol Cell (2008) 6.93
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol (2008) 6.90
Acetylation and deacetylation of non-histone proteins. Gene (2005) 6.87
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene (2002) 6.17
Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res (2004) 4.74
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem (2005) 4.62
The Dam1 kinetochore ring complex moves processively on depolymerizing microtubule ends. Nature (2006) 4.06
HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell (2007) 3.99
Formation of a dynamic kinetochore- microtubule interface through assembly of the Dam1 ring complex. Mol Cell (2005) 3.86
All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res (2003) 3.45
Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol (2011) 3.40
PRDI-BF1 recruits the histone H3 methyltransferase G9a in transcriptional silencing. Nat Immunol (2004) 3.39
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood (2010) 3.15
Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther (2009) 2.50
SIRT1 sumoylation regulates its deacetylase activity and cellular response to genotoxic stress. Nat Cell Biol (2007) 2.47
SIRT1 regulates the function of the Nijmegen breakage syndrome protein. Mol Cell (2007) 2.42
Regulation of histone deacetylase activities. J Cell Biochem (2004) 2.41
A critical role for Stat3 signaling in immune tolerance. Immunity (2003) 2.41
Skin stem cells orchestrate directional migration by regulating microtubule-ACF7 connections through GSK3β. Cell (2011) 2.36
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res (2006) 2.33
NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. J Natl Compr Canc Netw (2009) 2.25
Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review. Leuk Res (2011) 2.10
Targeted recruitment of a histone H4-specific methyltransferase by the transcription factor YY1. Genes Dev (2003) 2.08
Mice lacking the signaling molecule CalDAG-GEFI represent a model for leukocyte adhesion deficiency type III. J Clin Invest (2007) 2.05
Functional domains of histone deacetylase-3. J Biol Chem (2002) 2.05
Histone deacetylase 3 interacts with and deacetylates myocyte enhancer factor 2. Mol Cell Biol (2006) 2.01
Identification of compounds that enhance the anti-lymphoma activity of rituximab using flow cytometric high-content screening. J Immunol Methods (2004) 1.96
Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression. Curr Opin Genet Dev (2003) 1.95
Histone deacetylase 3 (HDAC3) activity is regulated by interaction with protein serine/threonine phosphatase 4. Genes Dev (2005) 1.94
Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res (2005) 1.93
Role of Stat3 in regulating p53 expression and function. Mol Cell Biol (2005) 1.91
SNARE proteins: one to fuse and three to keep the nascent fusion pore open. Science (2012) 1.89
Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion. Cancer Res (2008) 1.88
JNK phosphorylation relieves HDAC3-dependent suppression of the transcriptional activity of c-Jun. EMBO J (2003) 1.67
Structural basis for the modular recognition of single-stranded RNA by PPR proteins. Nature (2013) 1.66
Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther (2008) 1.65
Regulation of histone deacetylase 2 by protein kinase CK2. J Biol Chem (2002) 1.63
Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens. Leuk Res (2010) 1.63
Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. Clin Cancer Res (2005) 1.62
Chromatin unfolding by Cdt1 regulates MCM loading via opposing functions of HBO1 and HDAC11-geminin. Cell Cycle (2010) 1.62
Negative regulation of histone deacetylase 8 activity by cyclic AMP-dependent protein kinase A. Mol Cell Biol (2004) 1.60
Structural intermediates in microtubule assembly and disassembly: how and why? Curr Opin Cell Biol (2006) 1.58
Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res (2006) 1.58
Coactivators and corepressors of NF-kappaB in IkappaB alpha gene promoter. J Biol Chem (2005) 1.57
Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol Cancer Ther (2006) 1.56
Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res (2003) 1.56
Chromosomally integrated human herpesvirus 6: questions and answers. Rev Med Virol (2011) 1.50
Surgical management and evaluation of prognostic factors influencing postoperative visual outcome of suprasellar meningiomas. World Neurosurg (2011) 1.49
HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood (2008) 1.47
A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma (2011) 1.47
Endoplasmic reticulum stress induction of the Grp78/BiP promoter: activating mechanisms mediated by YY1 and its interactive chromatin modifiers. Mol Cell Biol (2005) 1.46
Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther (2003) 1.45
Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol Cancer Ther (2007) 1.45
Expansion of myeloid suppressor cells in SHIP-deficient mice represses allogeneic T cell responses. J Immunol (2004) 1.42
Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin Cancer Res (2007) 1.42
Structural mechanisms underlying nucleotide-dependent self-assembly of tubulin and its relatives. Curr Opin Struct Biol (2006) 1.41
Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood (2010) 1.41
Structural insight into the mechanisms of enveloped virus tethering by tetherin. Proc Natl Acad Sci U S A (2010) 1.39
Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene (2002) 1.38
Increased vascular senescence and impaired endothelial progenitor cell function mediated by mutation of circadian gene Per2. Circulation (2008) 1.36
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood (2006) 1.36
SIRT1 deacetylates the DNA methyltransferase 1 (DNMT1) protein and alters its activities. Mol Cell Biol (2011) 1.35
Regulation of Bax activation and apoptotic response to microtubule-damaging agents by p53 transcription-dependent and -independent pathways. J Biol Chem (2004) 1.32
Comprehensive association analysis of nine candidate genes with serum 25-hydroxy vitamin D levels among healthy Caucasian subjects. Hum Genet (2010) 1.31
Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol Cancer Ther (2007) 1.30
Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood (2004) 1.30
Activation of the growth-differentiation factor 11 gene by the histone deacetylase (HDAC) inhibitor trichostatin A and repression by HDAC3. Mol Cell Biol (2004) 1.26
Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clin Cancer Res (2004) 1.25
A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer. Proteomics Clin Appl (2011) 1.25
FtsZ protofilaments use a hinge-opening mechanism for constrictive force generation. Science (2013) 1.25
Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood (2005) 1.23
Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clin Cancer Res (2007) 1.23
Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin Cancer Res (2008) 1.23
Bax plays a pivotal role in thapsigargin-induced apoptosis of human colon cancer HCT116 cells by controlling Smac/Diablo and Omi/HtrA2 release from mitochondria. Cancer Res (2003) 1.22
Identification of a functionally impaired positive regulatory domain I binding factor 1 transcription repressor in myeloma cell lines. J Immunol (2003) 1.22
Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer. Clin Cancer Res (2003) 1.20
Bowl-shaped oligomeric structures on membranes as DegP's new functional forms in protein quality control. Proc Natl Acad Sci U S A (2009) 1.19
Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells. Blood (2004) 1.18
Physical and functional interactions of histone deacetylase 3 with TFII-I family proteins and PIASxbeta. Proc Natl Acad Sci U S A (2002) 1.16
The transcriptional repressor Sp3 is associated with CK2-phosphorylated histone deacetylase 2. J Biol Chem (2002) 1.15
SIRT1 negatively regulates the activities, functions, and protein levels of hMOF and TIP60. Mol Cell Biol (2012) 1.15
The ATDC (TRIM29) protein binds p53 and antagonizes p53-mediated functions. Mol Cell Biol (2010) 1.14
Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family. Cancer Res (2006) 1.13
In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity. Blood (2005) 1.13